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Abstract
Background: There is much evidence that tumor cells elicit a humoral immune response in patients. In
most cases, the presence of antibodies in peripheral blood is detected only in small proportion of patients
with tumors overexpressing the corresponding antigen. In the present study, we analyzed the significance
of local humoral response provided by tumor-infiltrating lymphocytes in breast cancer patients.
Methods: The ability of a patient's immune system to produce specific antibodies inside tumor tissue,
capable of recognizing tumor cells, was explored through analysis of the oligoclonality of antibodies
derived from tumor-infiltrating lymphocytes and construction of a series of recombinant antibody libraries
in scFv format, derived from breast tumor-infiltrating B lymphocytes. These libraries and one from
peripheral blood lymphocytes of a single breast cancer patient were panned against three purified surface
tumor antigens, such as CEA, MUC1 and ED-B domain, and against intact MCF7 breast carcinoma cells.
Results: Application of novel display vector, pKM19, allowed isolation of a large panel of breast cancer-
specific antibodies against known tumor antigens, as well as against breast carcinoma cells. Reactivity of
novel scFvs was confirmed by ELISA, immunohistochemistry, fluorescence staining and flow cytometry.
We demonstrated that seven of ten primary breast tumor specimens, obtained using discarded surgical
material, could be exploited as an appropriate source for generation of phage display libraries, giving highly
specific antitumor antibodies which recognize heterologous tumor cells.
Conclusion: Local humoral immune response within tumor tissue in breast cancer patients frequently
has an oligoclonal character. Efficient selection of specific antitumor antibodies from recombinant antibody
libraries, derived from such oligoclonal tumor-infiltrated B lymphocytes, indicates the presence of natural
immune response against tumor antigens in these patients. The described method is very promising for
development of antitumor antibodies, potentially useful for diagnostic and therapeutic approaches.
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Background
The discovery of monoclonal antibody technology [1]
stimulated rapid development of targeted therapies
against cancer. The use of monoclonal antibodies as a
drug delivery vehicles, or trigger for human immune
response is already an accepted method for therapeutic
treatment of patients in modern clinical oncology [2,3].
However, initially promising mouse monoclonal anti-
bodies induced development of anti-mouse immune anti-
body response (HAMA) in patients under repeated
monoclonal antibody administration, thus limiting their
application [4]. Recombinant DNA technology provides a
cheap, useful alternative to monoclonal antibody produc-
tion, allowing generation of large human recombinant
antibody libraries displayed on the surface of filamentous
phage and selection of specific human antibodies against
desirable targets, useful for therapy [5-8]. Moreover,
phage display also enables affinity maturation of antibod-
ies  in vitro through construction of mutant antibody
libraries, giving clones of greater affinity [9,10].
The possibility of finding high-affinity binders in a recom-
binant antibody library depends on its quality, which is
dependent on several factors, such as library size, diversity
and source of immunoglobulin genes. It is known that
various lymphoid tissues from immunized or nonimmu-
nized donors, such as peripheral blood lymphocytes
[11,12], spleen and bone marrow [13] and even metasta-
sized or drained lymph node tissue from individuals with
tumors [14-18] may serve as a source of specific antibody
repertoire. Although naïve antibody libraries are more
diverse and lead to isolation of antibodies with broad spe-
cificities, it is reasonable to suggest that construction of a
recombinant antibody library from the immunoglobulin
repertoire of someone affected by tumor can provide anti-
body fragments of higher binding affinity against specific
tumor antigens. Early evidence that tumor-infiltrating B
lymphocyte (TIL-B)-derived antibodies may also recog-
nize tumor cells was obtained in the following ways: by
production of human hybridomas derived from TIL, able
to secrete tumor-specific antibodies [19,20]; B cell expan-
sion of TIL from human tumor biopsies [21]; B cell expan-
sion of melanoma-derived TIL, and following cloning of
the scFv antibody with specific melanoma reactivity from
single B cell clone [22]; and subcutaneous transplantation
of human lung cancer tissue in immunodeficient mice
[23,24], all of which suggest a specific function of TIL-B in
the tumor. Recently, a rare type of breast cancer, classified
as medullary carcinoma (MCB, medullary carcinoma of
breast), characterized by strong lymphoplasmacytic infil-
trates correlated with improved prognosis and patient sur-
vival, and cervical carcinoma, were investigated to
understand the nature of tumor-infiltrated B lymphocytes
through analysis of TIL-derived Ig repertoire [25-28]. A
study of the molecular structure of variable antibody
regions gave evidence of antigen-driven humoral immune
responses in medullary breast carcinomas, as well as in
cervical tumors. The oligoclonal predominance found in
antibody genes derived from TIL indicated possible clonal
selection of the Ig molecules against specific neoantigens
overexpressing, or specifically expressing, in tumor tissue.
Despite the very strong above-mentioned indications that
tumor tissue is infiltrated with activated B cells, which
may serve as a source of tumor-specific antibodies, in pan-
ning experiments performed against purified known
tumor antigens, living tumor cells or frozen tissue sec-
tions, several research groups failed to select either a spe-
cific antibody discriminating between tumor and normal
cells, or one reactive with cell-surface tumor antigens
[26,27,29]. Only later, two different groups managed to
identify specific antibodies recognizing tumor cells from
this type of phage-display libraries [30,31].
Despite the limited success obtained by other research
groups exploring the recombinant antibody libraries
derived from TIL-B, we generated a series of TIL-B-based
scFv libraries from breast tumors. We panned them, along
with a peripheral blood lymphocyte (PBL)-derived library
from a single breast tumor patient, on living MCF7 breast
carcinoma cells, as well as on three purified tumor surface
antigens, i.e., CEA (carcinoembryonic antigen) [32],
MUC1 (epithelial mucin) [33] and ED-B domain of
fibronectin [34]. A novel pKM19 vector [35], designed to
provide relatively low expression levels of recombinant
antibodies, thus reducing biological bias for their expres-
sion in E. coli, was used for generation of antibody librar-
ies in scFv format. Cell-based panning and selection of
scFv antibodies against purified antigens provided, in
each case, a panel of highly specific antibodies from TIL-
or PBL-derived scFv libraries.
Methods
Tissue and blood samples
Specimens of breast carcinoma and fresh peripheral blood
from breast cancer patient EC23 were obtained from M.
G. Vannini Hospital, Rome. All human biological samples
were obtained through informed consent.
Cell lines
The breast carcinoma cell lines MCF7 (ATCC nr: HTB-22),
MDA-MB-468 (ATCC nr: HTB-132) were maintained in
DMEM/F12, supplemented with 5% FBS and used for cell-
based panning or for cell-ELISA. Immortal breast epithe-
lial cells MCF10-2A (ATCC nr: CRL-10781) [36] were
propagated according to manufacturer's instructions and
used as negative controls in ELISA tests. Human foreskin
fibroblasts (HFF) were cultivated in DMEM supplemented
with 10% FBS and 1% L-glutamine.BMC Biotechnology 2007, 7:70 http://www.biomedcentral.com/1472-6750/7/70
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Purified tumor antigen proteins
Human CEA protein, purified from human colon carci-
noma and liver metastases, was purchased from USBio-
logical (#C1300-16, United States Biological,
Swampscott, MA).
Biotinylated recombinant ED-B domain of fibronectin
was obtained from Sigma-Tau, Pomezia, Rome.
Recombinant MUC1 protein was obtained in several
steps. Two overlapping oligonucleotides KM358 5'-ACT
TCA GCT CCG GAC ACC CGT CCG GCT CCG GGT TCC
ACC GCT CCG CCG GCT CAC GGT GTC-3' and KM359
5'-CGG AGC CGG ACG GGT GTC CGG AGC TGA AGT
GAC ACC GTG AGC CGG CGG AGC GGT GGA ACC-3',
encoded for MUC1 20 amino acid repeat, were assembled
in PCR-like process, in which 25 cycles of PCR amplifica-
tion were performed with KM358 and KM359 primers in
a concentration of 0.2 mM. The high-weight DNA band
was then cut from agarose gel and ligated with a short
adapter, obtained by annealing an oligonucleotide
KM328 5'-CT AGT TCG TCG GGT TCG TCG GGA-3' with
a phosphorylated KM329 5'-TCC CGA CGA ACC CGA
CGA A-3', thus facilitating cloning of the blunt-end DNA
fragment in the SpeI site. The resulting DNA fragment was
purified from adapter excess, phosphorylated and cloned
into digested and dephosphorylated pGEX-SN [37],
derived from the pGEX-3× plasmid [38]. GST-fused
MUC1 recombinant protein, containing a 107 amino acid
MUC1 sequence, containing 5.3 repeats, was purified by
using Glutathione Sepharose 4B (Amersham Biosciences,
Uppsala, Sweden) according to manufacturer's instruc-
tions.
Purification of peripheral blood lymphocytes
The lymphocytes were isolated from 10 mL of fresh
peripheral blood mixed with anticoagulant by using
Ficoll-Paque Plus (Amersham Pharmacia Biotech, Upp-
sala, Sweden) according to manufacturer's instructions.
The mRNA was isolated from lymphocytes by using Dyna-
beads mRNA DIRECT Kit (Dynal, Oslo, Norway).
RNA extraction and cDNA synthesis
We obtained tumor specimens of about 200 mg from
breast carcinoma patients from discarded surgical sam-
ples, which were immediately frozen in liquid nitrogen.
Total RNA from frozen tumor specimens was prepared by
using Total RNA Isolation System (Promega, Madison,
WI) and subsequently used to purify mRNA using PolyAT-
ract mRNA Isolation System (Promega) according to man-
ufacturer's instructions. About 500 ng of poly(A)+ RNA
from breast carcinomas or 1 µg of the poly(A)+ RNA from
peripheral blood lymphocytes were used to synthesize
full-length cDNAs by using a SMART cDNA Library Con-
struction Kit (Clontech, Palo Alto, CA).
Analysis of antibody gene expression by PCR
The hypervariable V(D)J antibody region was amplified
by PCR from cDNA templates by using site-specific prim-
ers 5'-GGA CAC GGC T(G/C) TGT ATT ACT G-3' and 5'-
GCT GAG GAG ACG GTG ACC-3', designed in a study by
Hansen and colleagues [27]. IgG1, IgG2 and IgA subclass
determination was done as described earlier [39] by indi-
vidually combining constant region-specific primers for
IgG1, IgG2 and IgA genes (CG1d, CG2a and CA1, respec-
tively) with a set of variable heavy chain primers: VH135,
VH3a, VH3f, VH4, VH4b. These primers were designed for
construction of human Fab libraries [40].
ScFv library construction
The antibody gene repertoire was amplified using a set of
primers designed for amplification of VH and VL antibody
domains [41], and scFv fragments were assembled in vitro
as described earlier [41]. The scFv fragments were then
amplified by PCR with appropriate extension primers,
incorporating NcoI, NotI restriction sites, facilitating the
cloning of the scFv genes into the pKM19 vector. The
resulting PCR products were purified by agarose gel elec-
trophoresis (NuSieve 3:1 agarose, Rockland, ME). The
DNA fragments were digested with NcoI/NotI and inserted
into the pKM19 digested vector. Ligated DNA was used to
transform competent DH5αF' bacterial cells (supE44  ∆
lacU169 (φ 80 lacZ∆M15) hsdR17 recA1 endA1gyrA96 thi-
1 relA1 F' [traD36 proAB+ lacIqlacZ∆M15]) by electropora-
tion. The transformed cells were plated on 20 agar dishes
(ø 15 cm), containing LB agar, 100 µg/mL ampicillin and
1% glucose. After overnight incubation at 37°C, bacterial
colonies were scraped from the plates and resuspended in
LB, containing 10% glycerol. Aliquots of this cell suspen-
sion were stored at -80°C and used for phage amplifica-
tion.
Phage amplification
Forty µL of scraped bacterial cells were incubated in 40 mL
of LB containing ampicillin and 1% glucose until O.D. =
0.2. The bacteria were collected by centrifuging and resus-
pended in 40 mL of LB with ampicillin without glucose.
About 6 × 109  PFU (plaque-forming units) of helper
M13K07 were added to each mL of cell suspension, incu-
bated for 15 min at 37°C without agitation and for
another two h in a shaker. Kanamycin was added to
obtain a final concentration of 20 µg/mL, and cells were
incubated overnight at 32°C. Phage was purified accord-
ing to standard PEG/NaCl precipitation [42].BMC Biotechnology 2007, 7:70 http://www.biomedcentral.com/1472-6750/7/70
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Cell-based selection of antibodies from phage-displayed 
library
MCF7 semiconfluent cells (about 2 × 107) were rinsed
three times with PBS and incubated with 2 mL of 2 mM
EDTA in PBS for 15 min at 37°C. Ten mL of PBS contain-
ing 10 mM MgCl2 were added to the cells, which were
accurately collected by pipetting. The cells were pelleted
by centrifuging, washed once with 10 mL of PBS/MgCl2
and finally resuspended in 1 mL of freshly prepared block-
ing buffer: 4% non-fat dry milk, 0.05% Tween 20, 5 × 1011
PFU of f1 UV-killed phage in PBS. The cells were blocked
for 30 min at RT on rotating wheel, then collected and
incubated for one h at 37°C on the wheel with about 5 ×
1011 TU (transducing units) of freshly amplified scFv anti-
body library in 1 mL of blocking buffer. The cells were
washed five times with PBS/Tween and the bound phage
eluted by adding 400 µL of 0.1 M HCl, pH 2.2 (adjusted
by glycine). Cell suspension was incubated with elution
solution for ten min at RT, neutralized by 40 µL of 2 M
Tris-HCl, pH 9.6, and used for infection of bacterial cells.
The bacteria were plated on two LB agar dishes (ø 15 cm),
containing 100 µg/mL ampicillin and 1% glucose.
Scraped bacteria were used for phage amplification.
Affinity selection on purified protein targets
CEA and recombinant MUC1 were biotinylated as
described earlier [43]. About 5 × 1011 TU of freshly ampli-
fied scFv antibody libraries were preincubated with 50 µL
of AD202 bacterial extract in blocking buffer for 30 min at
37°C. Twenty µg of a biotinylated protein (CEA, MUC1 or
ED-B domain) were added to the reaction mixture and
incubated for another h at 37°C under gentle agitation.
The bound phage was captured by using streptavidin-
coated Dynabeads M-280 (112.05, Dynal) according to
manufacturer's instructions, washed five to ten times with
PBS/Tween, then eluted and amplified as above.
ELISA
The cells were grown in a 96-well plate until almost con-
fluent. After discarding the growth medium, 100 µL of
freshly prepared 4% paraformaldehyde (#15710, Electron
Microscopy Science, Hatfield, PA) in PBS were rapidly
added to well and incubated for ten min. The fixing solu-
tion was removed by pipetting and cells were incubated
with blocking buffer (5% milk, in PBS) for 30 min at RT.
PEG-purified phage in blocking buffer (1:1) was added to
the cells and incubated for one h at 37°C under gentle agi-
tation. The cells were washed three times with washing
buffer (0.05% Tween 20 in PBS) and incubated with an
anti-M13 HRP-conjugated antibody (27-9421-01, Amer-
sham Biosciences, Piscataway, NJ) for 30 min at 37°C.
The cells were washed five times and the immunoreaction
developed by incubation with TMB liquid substrate
(T8665, Sigma) for 15 min at RT and stopped by the addi-
tion of 25 µL 2 M H2SO4. The results were expressed as the
difference between absorbances at 450 and 620 nm, deter-
mined by an automated ELISA reader. All assays were
done in triplicate.
To test phage-antibody reactivity against soluble antigens,
a protein solution at a concentration of 10 µg/mL in 50
mM NaHCO3, pH 9.6, were coated overnight at 4°C into
Multiwell plates (Immunoplate Maxisorb, Nunc,
Roskilde, Denmark). After discarding coating solution,
plates were blocked for one h at 37°C with blocking
buffer (5% milk, 0.05% Tween 20 in PBS). Plates were
washed several times with washing buffer (0.05% Tween
20 in PBS). PEG-purified phage in blocking buffer (1:1)
was added to each well and incubated for one h at 37°C.
The immunoreaction was developed as above. All assays
were done in duplicate.
Soluble antibody production
Once identified, the scFv genes were recloned in pKM16
[35] for production of soluble antibodies. This plasmid
directs protein expression under the control of the lacP
promoter. The unique NcoI and NotI cloning sites facili-
tate insertion of antibody genes, allowing for expression
of single-chain antibodies as fusion to the leader peptide
and the first two amino acids of bacterial alkaline phos-
phatase, at the antibody's amino terminus, and as fusion
to FLAG/6His-tail at the antibody's carboxy terminus.
A single colony was inoculated into 50 mL of LB contain-
ing 100 µg/mL Ap and 2% glucose. The culture was grown
at 37°C for two to three h until O.D.600 = 0.8. The cells
were recovered by centrifugation, resuspended in 50 mL
of fresh LB with 100 µg/mL Ap, 1 mM IPTG, 20 mM
MgCl2, and incubated overnight at 30–32°C. Bacterial
cells were pelleted and then resuspended in 0.5 mL of
PBS. After three cycles of freeze and thaw, cell debris was
pelleted and the soluble antibodies purified from the
resulting supernatant by using HIS-Select HF Nickel Affin-
ity Gel (H-0537, Sigma), according to manufacturer's
instructions.
Immunohistochemistry
To study the specificity of scFvs, about 105 cells were spun
down onto each poly-L-lysine-covered glass slide. The
slides were processed according to standard protocols and
binding revealed using Vectastain ABC (Vector Laborato-
ries, Burlingame, CA). Briefly, the cells were fixed for 20
min with 4% formaldehyde at RT or for ten min with cold
methanol at -20°C, while endogenous peroxidase was
blocked with 3% H2O2 in PBS for five min. After two
washes with PBS, slides were blocked with 3% BSA in PBS
for 30 min and then incubated for one h at RT (with 10
µg/mL of scFv). The slides were washed again and incu-
bated for one h at RT with 10 µg/mL anti-FLAG HRP-con-
jugated monoclonal antibody (Sigma). After furtherBMC Biotechnology 2007, 7:70 http://www.biomedcentral.com/1472-6750/7/70
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washing, the slides were incubated with avidin-biotin-per-
oxidase complex for 30 min. Finally, DAB substrate (Vec-
tor Laboratories) was added and the reaction was stopped
after two to ten min by washing in tap water. Counter-
staining was performed with Mayer's hematoxylin (Vector
Laboratories) for ten s. Then the slides were dehydrated by
emerging into 75%, 80%, 95% and 100% ethanol solu-
tions and clarified twice for two min in histolemon (Carlo
Erba, Milan, Italy).
Before processing the non-fixed cells, the slides were air-
dried for ten min and then used for staining.
Frozen tissue slices were thawed for one h at RT and
hydrated with PBS. The slices were fixed with acetone for
10 min at RT and blocked with blocking solution (1.5%
horse serum in PBS) for 30 min. The scFv antibodies, in a
concentration of 10 µg/mL in blocking solution, were
added to the slides for 30 min. The slides were then proc-
essed as above.
Immunofluorescence staining
The cells were grown in a 24-well plate for cell culture
(Nunc, Roskilde, Denmark), fixed with 3.7% formalde-
hyde in PBS for 10 min at RT and blocked with 3% BSA in
PBS for one h at RT. PEG-purified phage in 1% BSA/PBS
was added to the cells and incubated for one h under gen-
tle agitation at 37°C. The cells were washed three times
with 1% BSA in PBS and incubated with an anti-M13
mouse monoclonal antibody (27-9420-01, Amersham
Biosciences) for 30 min at 37°C. The cells were washed as
above and then incubated with an FITC-conjugated anti-
mouse goat polyclonal antibody (554001, BD Biosciences
Pharmingen, San Jose, CA) at a concentration of 5 µg/mL
for 30 min at 37°C under gentle agitation. After the last
incubation, cells were washed five times, dried in the dark,
mounted with Vectashield medium (Vector Laboratories,
Inc. Burlingame, CA) and cover glasses and analyzed
using an inverted fluorescence microscope.
Fluorescence-activated cell sorting (FACS) analysis
One hundred µL of phage suspension in TE (about 3 ×
1010 TU) were preincubated with 50 µL of 4% non-fat
dried milk in PBS buffer for 15 min at RT under agitation
to block unspecific binding. The phage sample was then
added to 5 × 105 human cells in 50 µL of 1% BSA in PBS
and incubated for one h at 4°C in a 96-well plate. After
two washings with 1% BSA in PBS, a murine anti-M13
monoclonal antibody, diluted 1/50, was added to cell pel-
let and incubated for 30 min at 4°C. Afterwards, the cells
were washed as above and incubated with an anti-mouse
PE-conjugated antibody (550589, BD Biosciences
Pharmingen), diluted 1/100, for another 30 min at RT.
After staining, the cell samples were washed twice. Specific
binding of the phage particles displaying scFv antibodies
was measured by FACSArray or FACSCalibur instrument
(BD Biosciences, Franklin Lakes, NJ). Viability detection
was performed by adding 2.5 µL of 7-AAD staining solu-
tion (559925, BD Biosciences Pharmingen) to each sam-
ple.
For FACS analysis with soluble scFv antibodies about 5 ×
105 cells were resuspended in 1% BSA in PBS and incu-
bated, first with 2 µg of a purified scFv primary antibody,
then with an anti-Flag antibody (F3165, Sigma) and
finally with a FITC-labeled anti-mouse-IgG (F0257,
Sigma), following manufacturer's instructions. Incuba-
tion was performed for 30–45 min in ice-water bath, the
cells washed between steps with 1% BSA in PBS.
In case of intracellular staining, the cells were fixed by 4%
cold formaldehyde in PBS for 5 min in ice and resus-
pended in 1% BSA, 0.5% Saponin (S1252, Sigma) in PBS.
The cells were processed as above and washed between the
steps with 1% BSA, 0.5% Saponin in PBS. Final washings
were performed reducing the amount of saponin from 0.1
to 0.001 and then 0%. The samples resuspended in PBS
were then acquired and analyzed by Cell quest software
on FACSCalibur.
Results
Characterization of the lymphoplasmacytic cell infiltrates 
in breast tumor samples
We examined ten tumor specimens from breast cancer
patients (aged 47–79) for presence and nature of TIL-B,
first by PCR amplification of V(D)J antibody segments
(CDR3, complementarity-determining region 3) and then
by a comparison between IgG and IgA antibody classes
presenting in tumor samples.
We analyzed the expression patterns of the antibody frag-
ment genes by semi-quantitative PCR from SMART cDNA
template. A panel of cDNAs from ten breast carcinomas
and samples of normal breast, testis and peripheral blood
lymphocytes from healthy donors were normalized by
PCR amplification of β-actin, a housekeeping gene (Fig.
1a). Hypervariable heavy chain antibody regions (V(D)J)
were amplified as described in Materials and Methods.
After analysis by agarose gel electrophoresis, the PCR sam-
ples were also fractionated by high resolving 10% PAGE
(Fig. 1b). In applying this technique, we observed that
seven of ten tumor-derived samples contained various dis-
crete bands, characterizing oligoclonality of the immune
response in these patients, while the well-amplified nor-
mal breast and peripheral lymphocyte DNA fragments did
not contain intensive bands but formed a smear, consist-
ing of bands of differing length. The observed oligoclonal-
ity of the immunoglobulins did not correlate with the age
of the patients.BMC Biotechnology 2007, 7:70 http://www.biomedcentral.com/1472-6750/7/70
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Analysis of oligoclonality of TIL-derived antibodies Figure 1
Analysis of oligoclonality of TIL-derived antibodies. (a) V(D)J analysis of TIL-derived antibody genes. SMART cDNA 
derived from ten different tumor samples (patients B84, B85, B87, B89, B90, B91, B92, B93, B95, B96), normal breast, normal 
testis and peripheral blood lymphocytes from four healthy donors (L1, L2, L3, L4), was used, as template for amplification of 
V(D)J antibody regions. Samples of cDNA were normalized by amplification of β-actin housekeeping gene. All V(D)J fragments 
were well-amplified and gave DNA bands of expected molecular weight in all cases, excluding normal testis cDNA sample. (b) 
The same PCR products were fractionated by 10% PAGE, giving a higher resolution of DNA bands. (c) Antibody subclass dis-
tribution. PCR-amplified normal breast and B84 cDNA samples not showing oligoclonal bands in V(D)J test, have prevalence of 
IgA bands in comparison to IgG1 and IgG2 (left panels), while three samples, B91, B92 and B93, giving strong oligoclonal bands 
in previous test, have IgG1 or both IgG1 and IgG2 band prevalence in comparison with IgA (right panels). (d) Clonality of heavy 
chain antibodies derived from B92 and B93 cDNA samples. Amino acid sequences of variable regions of 30 clones were 
deduced from randomly sequenced γ-chain antibody genes derived from B92 and B93 cDNA. Peptide sequences are reported 
in single-letter code. Identical amino acids in similar clones are represented by a dash.BMC Biotechnology 2007, 7:70 http://www.biomedcentral.com/1472-6750/7/70
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To analyze antibody subclass distribution we amplified Ig
genes from breast carcinoma cDNA and normal breast,
using subclass-specific primers. In agreement with the pre-
vious assay, the 3 cDNA tumor samples without oligo-
clonal bands in PCR-amplified V(D)J regions, had, in this
test, a prevalence of IgA in comparison with IgG1 and
IgG2 bands, just as in a sample of normal breast where IgA
generally represents the major Ig class [44]. On the other
hand, samples showing oligoclonality in the first assay
contained IgG1, or both IgG1 and IgG2 as dominant anti-
body bands, in contrast to normal breast. Fig. 1c shows
four more characteristic examples, along with normal
breast sample. The cDNA samples from patients B85, B87,
B91, B92, B93, B95 and B96 were chosen for library con-
struction. Sample B85, which did not provide strong oli-
goclonal bands, nevertheless showed a prevalence of IgG
antibodies (data not shown).
Oligoclonality of TIL-B-derived antibodies in breast cancer 
patients was confirmed by sequencing
We chose two cDNA samples (B92, B93) that gave the
strongest sharp bands in V(D)J test, for sequencing analy-
sis. The nucleotide sequences of 17 and 13 randomly
picked clones containing heavy chain genes deriving from
B92 and B93 cDNA, respectively, were determined and
their amino acid sequences deduced (Fig. 1d). All 30
clones encoded in-frame correctly organized heavy
chains. The antibody clones, B92A and B93A, occurring
more frequently, contained V(D)J regions of a length
exactly corresponding to the strong bands observed earlier
in Fig. 1b (lines with PCR products deriving from B92 and
B93 samples) (data not shown), thus indicating that both
PCR amplification with variable heavy chain primers and
the cloning step do not introduce any particular bias inter-
fering with heavy chain frequencies in generated libraries.
Six somatic mutations, identified in antibody fragments
isolated many times, were localized within variable CDRs
of VHs of the same specificity, while only one mutation
was found in FRs of 30 heavy chain sequences (P  =
0.0002). Therefore, the oligoclonality of the antibody rep-
ertoire, deriving from a tumor microenvironment, is a
natural immune response occurring within tumor tissue
driven by tumor antigens, and not an artifact introduced
by PCR amplification.
Library construction
Four scFv antibody libraries were generated using seven
cDNA samples, characterized by oligoclonality of the
immune response (see list of libraries in Table 1). Only
the scFvEC23 library was constructed earlier [35] from
peripheral blood lymphocytes, obtained from a single
patient with advanced breast cancer.
We used a novel pKM19 vector for construction of the
libraries [35]. This vector is characterized by the following
features: (i) use of the PhoA leader peptide (a genuine E.
coli periplasmic protein) guarantees efficient membrane
assembly and processing of recombinant antibodies; (ii)
relatively low antibody expression levels prevent abun-
dant protein production, reducing biological bias for
harmful antibodies that may affect bacterial growth or be
toxic for host bacteria, thus increasing the actual complex-
ity of a generated library; (iii) fusion of scFv antibody to
deleted gpIII protein improves antibody display efficiency
in this system.
Selection of specific antitumor antibodies from phage 
display libraries generated from TIL-B and PBL
We examined the possibility of selecting specific antibody
fragments from phage libraries against common cancer
antigens available in our lab, including ED-B domain of
fibronectin, MUC1 epithelial mucin, and CEA. Under
conditions described in Materials and Methods, a mixture
of four TIL-derived scFv libraries (mixTIL) and the
scFvEC23 library were panned separately against three
protein targets in several rounds. In every case, we
observed that phage pools were positive against the select-
ing antigen already after the second and third panning
rounds (data not shown). Randomly picked clones from
pools of phage after the third round of selection were
tested in ELISA for binding reactivity against the respective
antigens. Positive clones were analyzed by DNA finger-
printing using HaeIII and AluI double digestion and all
the various antibody clones were sequenced. Table 2 sum-
marizes the clone analysis data. Fig. 2 represents ELISA of
single scFv phages selected on purified antigens.
Table 1: List of libraries and mixtures
Library Source of Ig genes Patient(age) Library complexity
scFvB87 TIL B87 (55) 4.7 × 105
scFvB95 TIL B95 (73) 1.1 × 107
scFvB96 TIL B96 (72) 2.6 × 107
scFvmix TIL B85 (47), B91 (70), B92 (79), B93 (66) 2.4 × 107
scFvEC23 PBL EC23 (65) 1.8 × 107
mixTIL: scFvB87, scFvB95, scFvB96, scFvmix TIL
mixLIB: scFvB87, scFvB95, scFvmix, scFvEC23 TIL+PBLBMC Biotechnology 2007, 7:70 http://www.biomedcentral.com/1472-6750/7/70
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Cell-based selection of tumor-specific antibodies
We tested functionality of a single TIL-derived library
(scFvB96) by selecting breast cancer-specific antibodies
through cell-based panning on living MCF7 breast carci-
noma cells. Four additional libraries, including scFvB87,
scFvB95, scFvmix and scFvEC23, were pooled together
(mixLIB) and panned in similar fashion. Four or five
selection rounds on the tumor cells were necessary for
mixLIB and scFvB96 libraries, respectively, in order to
obtain phage pools enriched by specific cell binders (Fig.
3a). Then, randomly picked clones were analyzed by PCR
for presence of complete scFv antibody genes. The full-
length scFv phage clones were tested by cell-based ELISA,
and analyzed by DNA fingerprinting (Fig. 3b). Table 3
summarizes clone analysis data. All different positive
clones were sequenced. Amino acid sequences, deduced
from DNA sequences, confirmed correct, in-frame anti-
body structures.
The reactivity and specificity of cell-selected antibodies
were verified by ELISA on two breast carcinoma cell lines:
MCF7, MDA-MB-468 and normal cells, as negative con-
trols: MCF10-2A (normal human breast epithelium), HFF
(human foreskin fibroblasts) (Fig. 3c). Of ten different
antibodies belonging to seven specificity groups (MIX7,
MIX12, MIX25 have the same heavy chain sequence and
different light chains; MIX8 and MIX39 have similar
sequences with minor differences), nine scFvs specifically
bind to breast carcinoma cells, while the B96/4F antibody
alone also binds to normal epithelial cells as well.
Cell-selected antibodies derived from TIL
MIX7-MIX39 scFv antibodies were selected from a mixture
of PBL and TIL-derived libraries. We investigated the ori-
gin of these antibodies to see which type of library func-
tions better under equal selection conditions. One µL of
each amplified library was used as template for PCR
amplification with a pair of oligonucleotide primers spe-
cific for each antibody (Fig. 4). This analysis shows that
five tested scFv antibodies, isolated from a mixture of
libraries, belong to TIL-derived antibodies. Antibody
genes of MIX7 and MIX25 (having the same heavy chain
as MIX12), and MIX8 (similar to MIX39) are believed to
have a similar origin. Regarding the irrelevant anti-SP2
antibody, selected earlier from an scFvEC23 library [35],
its origin from a PBL-derived library was confirmed.
Staining of tumor cells
To demonstrate the specificity of selected antibodies we
examined three scFvs in soluble form (MIX7, MIX17 and
MIX39) by immunohistochemical staining. These anti-
bodies were chosen because of their good reactivity, spe-
ELISA reactivity of single phage antibodies Figure 2
ELISA reactivity of single phage antibodies. Reactivity 
of single phage clones after third round of selection against 
ED-B, MUC1 and CEA was tested using respective proteins. 
Data reported are the average values of assays performed in 
duplicate. Several irrelevant proteins and an anti-SP2 irrele-
vant phage antibody [35] are included as negative controls.
Table 2: Results of selection by using purified tumor antigens
Target 
antigen




ED-B mixTIL 10/10 1
ED-B scFvEC23 10/10 3
MUC1 mixTIL 2/16 1
MUC1 scFvEC23 6/8 2
CEA mixTIL 13/16 6BMC Biotechnology 2007, 7:70 http://www.biomedcentral.com/1472-6750/7/70
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cificity and stability in soluble form. The first staining was
performed on various methanol-fixed breast carcinoma
cells, including MCF7, MDA-MB-231 and MDA-MB-468
(Fig. 5a). Different intensity staining was observed for all
three antibodies tested, compared to the irrelevant anti-
SP2 antibody. In the second experiment, formaldehyde-
fixed or non-fixed dried cells were stained (Fig. 5b). All
selected antibodies specifically stained both fixed and
non-fixed carcinoma MCF7 cells, but did not stain normal
epithelial MCF10-2A cells. However, the signal was nota-
bly stronger for non-fixed cells. Weak background labe-
ling was registered for MIX39 when it interacted with non-
fixed MCF10-2A cells. Intensive staining activity of MIX17
and MIX7 was associated with the cell membrane, cyto-
plasm and nuclear membrane, while MIX39 staining was
of nuclear localization (Fig. 5c).
We also stained tumor and normal matched breast tissues,
available in our laboratory, from patients B93 and B95.
All the scFvs tested strongly stained tumor cells and were
negative with normal matched tissue from patient B93
(Fig. 6). The irrelevant anti-SP2 antibody did not react
with the tissue slices tested.
The binding capacity of the anti-MUC1 antibody MB5
and the anti-CEA antibody CB37 were assessed by
immunofluorescence staining of tumor cells directly with
phage antibodies (Fig. 7). The MB5 antibody intensively
stained MCF7 cells, known for high MUC1 expression,
and also reacted well with another breast carcinoma cell
line, SkBr3. The CB37, an anti-CEA antibody, efficiently
bound colon adenocarcinoma cells, LoVo, expressing the
carcinoembryonic antigen. No background staining for
normal breast epithelium was observed. Binding of the
MB5 and CB37 phage-displayed scFvs was also measured
by flow cytometry. According to FACS analysis, the MB5
stained 71% of MCF7 and 23.3% of ScBr3 cells. With
regard to the anti-CEA CB37 antibody, it bound 44% of
LoVo cells.
All anti-MCF7 phage clones were tested in fluorescence
staining of non-permeabilized MCF7 breast carcinoma
cells (Fig. 8) in comparison with normal MCF10-2A cells
(not shown). All antibodies stained only a low percentage
of MCF7 cells, probably apoptotic or dead cells. No back-
ground staining for normal breast epithelium was
observed. FACS analysis performed with three soluble
scFv antibodies confirmed that MIX antibodies react with
intracellular antigens of tumoral cells (Table 4).
Discussion
In comparison with the nondetectable clonality of B cells
in peripheral blood lymphocytes (<1/20,000), B cells
from tumor-draining lymph nodes and tumor-infiltrating
lymphocytes represent a much more limited Ig repertoire
[45]. About 7% of lymph node-derived, and between 18–
68% of TIL-derived, heavy chain antibody sequences
belong to clonal groups [45], thus indicating both tumor-
draining lymph nodes and tumor-infiltrating lym-
phocytes as promising sources of tumor-specific antibod-
ies. In fact, identification of anti-tumor recombinant
antibodies from display libraries derived from lymph
nodes of cancer patients was reported in several studies, as
mentioned in the Introduction [14,17,18]. However, we
found it quite difficult to obtain, as fresh surgical material,
metastasized or tumor-draining lymph nodes from breast
cancer patients. According to recent medical practice, the
surgeon removes only a sentinel lymph node, or a small
cluster of nodes (sentinel node and those closest to it),
instead of removing dozens of lymph nodes as before,
thus performing less invasive surgery and reducing side
effects. After sentinel lymph node dissection, practically
the entire node is studied for presence of micrometastasis
or single cancer cells. As a result, in breast cancer surgery,
the dissected node is virtually unavailable as discarded
surgical material.
In this article, we examined the possibility of using pri-
mary tumors as a source of genes of antitumor antibodies,
potentially useful for diagnostic and therapeutic
approaches. We showed, by PCR amplification of specific
antibody gene regions deriving from ten primary breast
tumors (none being of the rare MBC histological type) of
patients aged between 49–79 years, that seven of ten of
these samples (70%), have a prominent IgG antibody
expression, as compared with the IgA subclass. This corre-
lates with the oligoclonality of the hypervariable region of
heavy chain antibodies, suggesting a specific immune
response to tumor-expressed antigens. Clonality of
tumor-derived antibodies was confirmed by sequencing
analysis. The great majority of the gamma heavy chains,
derived from TIL-B of B92 and B93 patients, belong to
clonal groups. The higher frequency of somatic mutations
observed within CDRs vs FRs in variable regions of heavy
chains of the same specificity indicates that tumor-infil-
trated B-cells locally produce a restricted IgG repertoire,
with evidence of antigen-driven maturation.
Table 3: Results of cell-based selection
MCF7-based selection
Library scFvB96 mixLIB
Round of selection 5 4
Full-length scFvs/PCR-tested clones 12/40 30/40
ELISA positive/full-length clones 5/12 22/30
Isolated antibody genes 2 8BMC Biotechnology 2007, 7:70 http://www.biomedcentral.com/1472-6750/7/70
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Selection of anti-MCF7 antibodies Figure 3
Selection of anti-MCF7 antibodies. (a) Reactivity of phage pools after fourth and fifth rounds of panning, in comparison 
with original libraries, was tested. Data reported are the average values of assays performed in triplicate. (b) Fingerprinting 
analysis of antibody clones. PCR-amplified scFv genes were analyzed by using HaeIII and AluI double digestion. The analysis of 
clones 17–39, selected from mixLIB, is shown at right, and the list of different anti-MCF7 antibodies obtained shown at left. (c) 
Cell ELISA reactivity of single phage clones. Data reported are the average values of assays performed in triplicate. Cells devel-
oping with irrelevant anti-SP2 antibody are included as negative control.BMC Biotechnology 2007, 7:70 http://www.biomedcentral.com/1472-6750/7/70
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We identified a panel of tumor-specific antibodies from
the described libraries; these antibodies were reactive with
ED-B domain, MUC1, CEA and MCF7 breast carcinoma
cells used in the respective selections. It is interesting to
note that, in cell-based selection, performed without a
subtractive panning step on normal breast epithelium,
and in contrast with numerous previously described selec-
tion protocols [17,18,46-48], we isolated only one non-
specific scFv, which recognized normal breast epithelium
as well. This probably indicates that our modest-sized TIL-
derived libraries, despite a very restricted antibody reper-
toire, contain quite strong easily selectable antitumor
binders. The antibodies obtained in the cell-based selec-
tion, recognized intracellular antigens, as shown by fluo-
rescent and immunohistochemical staining, and flow
cytometry analysis. This result agrees with Hoogenboom's
findings, which demonstrated that local humoral
immune response in colorectal carcinoma patients was
biased toward intracellular target antigens [29]. Notably,
that antibody selection from a mixture of PBL- and TIL-
derived libraries clearly shows the latter to be more effi-
cient in cell-based panning. In fact, all isolated anti-MCF7
single-chain antibodies appeared to be derived from
tumor-infiltrating lymphocytes. The libraries derived
from TIL have quite low complexity, as it was shown by
random sequencing of antibody repertoire in two patients
(Fig 1d). For this reason, we presume that the efficient
selection of scFvs against various antigens tested is a result
of the strong antitumor profiles of such libraries and the
use of a suitable combination of antibody repertoires
from various patients. In order to understand how often
antibodies against a single antigen occur in different TIL-
derived repertoires, we attempted to select new anti-CEA
antibodies from a new mixture of libraries, this time
excluding the scFvB96 library, since one of the anti-CEA
antibodies, CB37, derived exactly from this library (Fig.
3c). No new antibodies were selected, indicating that
patient B96 alone, among seven patients, had local
immune response against the CEA antigen. However, in
order to reach a definitive conclusion on the capacity of
TIL-derived libraries, it would be interesting to compare
selection against the same antigens from TIL- and PBL-
derived libraries from the same patient. Unfortunately, we
have no such matched libraries.
To sum up, TIL-derived libraries gave good results in all
performed selections, providing a panel of human tumor-
specific antibodies which recognize tumor cell surface and
intracellular antigens.
As mentioned in the Background, the selection of specific
antitumor antibodies from TIL-derived phage-display
libraries often failed, while an alternative approach, based
on a phage-expression tumor-derived library and direct
plaque screening protocols that avoided the limitations of
a phage display system, allowed Wu and colleagues [49]
to isolate multiple antibodies that specifically bind cul-
tured tumor cells. In the present study, we applied a novel
pKM19 vector for display of recombinant antibodies in
single-chain format. We believe the application of the
improved display system permitted us to generate the
functional tumor-derived phage-display libraries, giving
rise to various antibodies that recognize tumor cell anti-
gens.
Conclusion
Our results indicate that natural immune responses to
tumor-related antigens occur quite frequently in patients
with breast cancer, not only in histologically-defined
MCB. Tumor samples as small as 0.2 g, obtained as surgi-
cal material, can be exploited as an appropriate source for
Origin of anti-MCF7 scFv antibodies Figure 4
Origin of anti-MCF7 scFv antibodies. One µL of each 
scFv phage library was amplified by PCR using oligonucle-
otide primers specific for analyzed antibody genes. Corre-
sponding PEG-purified phage was used as positive control 
(last line). The irrelevant anti-SP2 antibody gene of known 
origin, selected earlier from scFvEC23 library, was also 
tested.BMC Biotechnology 2007, 7:70 http://www.biomedcentral.com/1472-6750/7/70
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Immunohistochemical staining of tumor cells Figure 5
Immunohistochemical staining of tumor cells. (a) The scFvs MIX7, MIX17 and MIX39 show significant staining of the 
MCF7, MDA-MB-231 and MDA-MB-468 breast carcinoma cells. No staining is observed with the negative control (irrelevant 
anti-SP2 antibody). (b) Staining of breast carcinoma cells in comparison with normal breast epithelial cells MCF10-2A. The 
selected antibodies stain the non-fixed cells more intensively than the fixed MCF7 cells, but not the MCF10-2A cells. Weak 
background is observed only for MIX39 scFv when it interacts with MCF10-2A cells. No staining is observed for negative con-
trol anti-SP2 antibody. (c) Staining non-fixed MCF7 cells, magnification ×60.BMC Biotechnology 2007, 7:70 http://www.biomedcentral.com/1472-6750/7/70
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generation of recombinant phage display libraries
enriched for tumor-specific antibodies. Isolation of a
panel of antitumor scFvs through selection against desira-
ble protein targets, as well as against living breast carci-
noma cells, shows this approach to be very promising for
development of human antibodies, potentially useful for
diagnostic and therapeutic approaches.
Moreover, investigation of the protein targets eliciting
production of tumor cell-specific antibodies in a tumor
microenvironment may (i) provide important informa-
tion about individual immunoreactivity of a given
patient, affording a prognostic value; (ii) open an ample
perspective for discovery of novel tumor-specific antigens.
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Immunohistochemical staining of tumor tissues Figure 6
Immunohistochemical staining of tumor tissues. Slices of breast tumor tissue from patient B95 and matched breast 
tumor and normal tissues from patient B93 were stained with MIX7, MIX17 and MIX39 soluble antibodies and an irrelevant 
anti-SP2 antibody. Intensive staining tumor tissues were observed for all selected antibodies. MIX39 slightly stains matched 
normal breast tissue of patient B93.BMC Biotechnology 2007, 7:70 http://www.biomedcentral.com/1472-6750/7/70
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Fluorescence staining and flow cytometry with anti-MUC1 and anti-CEA antibodies Figure 7
Fluorescence staining and flow cytometry with anti-MUC1 and anti-CEA antibodies. (a) Fluorescence staining of 
breast carcinoma cells MCF7 and SkBr3, expressing epithelial mucin MUC1 and normal breast epithelial MCF10-2A cells by 
using phage antibody anti-MUC1 MB5 (left panels). Right panels show results of flow cytometry analysis of phage displayed MB5 
and irrelevant anti-SP2 single-chain antibodies. (b) Staining of LoVo colorectal adenocarcinoma cells expressing CEA protein by 
phage-displayed anti-CEA CB37 scFv antibody is shown. Staining of negative control MCF10-2A cells is included (left panels). 
Binding of phage antibody CB37 to LoVo was also measured by flow cytometry (right panels).BMC Biotechnology 2007, 7:70 http://www.biomedcentral.com/1472-6750/7/70
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Fluorescence staining with anti-MCF7 antibodies Figure 8
Fluorescence staining with anti-MCF7 antibodies. Fluorescence staining of breast carcinoma MCF7 fixed non-permeabi-
lized cells by phage antibodies. No staining of negative control MCF10-2A cells was observed (data not shown).
Table 4: Flow cytometry analysis of two MCF7 and MDA-MB-468 tumor cell lines and normal breast epithelial MCF10-2A cells. 
Irrelevant antibody anti-SP2 was used as negative control, while an α-tubulin monoclonal antibody was used as positive control for 
intracellular staining
Cell line/scFv antibody Surface staining of alive cells Intracellular staining
MCF7 % pos MFI* iMFI** % pos MFI iMFI
α-tubulin n.t. n.t. n.t. 88.04 684.49 60262.5
anti-SP2 2.73 24.45 66.7 0.36 4221.17 1519.6
MIX7 2.84 29.19 82.9 73.03 603.58 44079.4
MIX17 2.68 22.76 59.9 84.2 733.63 61771.6
MIX39 3.98 22.9 91.1 13.89 504.85 7012.4
MDA-MB-468 % pos MFI iMFI % pos MFI iMFI
α-tubulin n.t. n.t. n.t. 85.22 259.18 22087.3
anti-SP2 1.9 51.17 97.2 0.98 579.13 567.5
MIX7 3.93 40.4 158.8 37.14 214.39 7962.4
MIX17 5.38 33.04 177.8 70.54 260.36 18365.8
MIX39 3.33 30.04 100.0 2.51 237.64 596.5
MCF10-2A % pos MFI iMFI % pos MFI iMFI
α-tubulin n.t. n.t. n.t. 42.05 169.64 7133.4
anti-SP2 0.44 95.68 42.1 0.44 1515.5 666.8
MIX7 0.94 208.51 196.0 0.29 962.79 279.2
MIX17 0.81 11.84 9.6 1.06 824.83 874.3
MIX39 0.93 175.42 163.1 6.49 156.57 1016.1
* mean fluorescence intensity
** integrated MFI (% pos × MFI)
n.t.- not testedBMC Biotechnology 2007, 7:70 http://www.biomedcentral.com/1472-6750/7/70
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